Skip to main content




Any weight that is higher than normal body weight, caused by excessive fat tissue and an increase in fat cell size and number, is described as either being overweight or being obese (1).  In order determine if a person is obese, the World Health Organization (WHO) uses a screening tool called the Body Mass Index (BMI) which divides a person’s weight in kilograms by the square of their height in meters (2,3).  The score is then compared to the BMI chart and categorized. A person is considered overweight if their BMI is ≥25 or obese if their BMI is ≥30 (4).

Obesity can lead to the prevalence of other noncommunicable, chronic diseases including: type 2 diabetes, coronary heart disease, stroke, hypertension, cardiovascular disease (CVD), various forms of obesity-related cancers, insulin resistance, gallstones, respiratory system problem like asthma and sleep apnea, fatty liver, osteoarthritis, and gout (1,2,4,5,6,7).


The two main risk factors that contribute to obesity is individual behavior and environmental factors. Some literature suggests that genetics might also contribute to obesity, but results are inconclusive (4,7,9).

  • In terms of individual behavior, well-known predictors of obesity include overeating, low levels of physical activity, high baseline BMI, and pre-existing medical conditions.  High blood pressure, high cholesterol levels, or high blood sugar levels are all warning signs of some obesity-associated diseases. Other predictors of obesity can be how an individual is shaped (2).
  • In terms of environmental factors, an individual’s culture, access to education, food marketing, and promotion and opportunity to engage in physical activity are all factors that contribute to obesity (7,8).
  • Childhood obesity is also a predictor of becoming obese as an adult.


  • Breathlessness
  • Increased sweating
  • Snoring
  • Inability to cope with sudden physical activity
  • Tiredness


Over the last few decades, the prevalence of obesity has increased significantly and has now become a major health problem in developed countries and a growing one in the developing world (1).

  • In 2015-2016, the prevalence of obesity was 39.8% and affected about 93.3 million of U.S. adults (7).
  • In the United States, during 2015-2016, the prevalence of childhood obesity was 18.5% and affected about 13.7 million children and adolescents. Childhood obesity is also more common among certain populations with Hispanics (25.8%) and non-Hispanic blacks (22.0%) having a higher obesity prevalence than non-Hispanic whites (14.1%) and non-Hispanic Asians (11.0%) (7).
  • People with a family history of chronic diseases are more likely to develop these problems if they are obese (8).
  • The prevalence of obesity decreases as the level of education in people increases (7).


Pharmacologic treatment and therapy are used to supplement lifestyle changes to enable weight loss and prevent weight regain, however, it is not an appropriate solution for everyone. Current criteria for the use of pharmacologic therapy for obesity include a BMI above 30 or a BMI above 27 in the presence of coexisting conditions (4).

The Food and Drug Administration (FDA) has only approved the following drugs for treatment:

Sibutramine: a serotonin-norepinephrine reuptake inhibitor that reduces appetite.

  • Common side effects include hypertension and tachycardia (11)

Phentermine diethylpropion: a stimulant that enhances the release of the chemical norepinephrine to reduce food intake.

  • Side effects included palpitations, tachycardia, elevation of blood pressure, central nervous system effects, and gastrointestinal effects. Blood pressure should be monitored closely for participants with prehypertension or are being treated for hypertension. It is usually not the first choice to treat weight loss and has been approved for short term use only (10).

Orlistat: a triacylglycerol lipase inhibitor that reduces the amount of fat absorbed by the body (12).

  • Side effects may include oily spotting, gas with discharge, and diarrhea (13).


Practices to Support a Healthy Weight:

  • Early Intervention (7)
  • Diet
  • Physical Activity (4)
  • Behavioral Modification (14)

Natural Supplements that Support a Healthy Weight:

  • African mango (15)
  • Aloe Vera (16)
  • Alpha-Lipoic acid (17,18,19)
  • Beta-glucans (15)
  • Black wattle (Acacia mollissima) (20)
  • Blond Psyllium (21,22,23,24)
  • Blueberry (Vaccinium ashei) (20)
  • Caffeine (25,26,27,28,29,30,31)
  • Calcium (32,33,34,35,36)
  • Capsaicin (15,37)
  • Caralluma fimbriata (15)
  • Chili pepper (Capsicum annuum) (20)
  • Coffee (Coffea Arabica) (20)
  • Coleus forskohlii (38)
  • Conjugated linoleic acid (38,39,40,41,42,43,44,45)
  • Coptis Root (Rhizoma coptidis) (20)
  • Fucoxanthin (15)
  • Garcinia cambogia(15)
  • Ginger (Zingiber officinale) (20)
  • Glucomannan(15)
  • Green coffee bean extract (15)
  • Guar gum (15)
  • Maté tea (Ilex paraguariensis) (20)
  • Mulberry (Morus australis) (20)
  • Phaseolus vulgaris (Red kidney beans) (15)
  • Probiotics (15)
  • Pyruvate (15)
  • Soybean (Glycine max) (20)
  • Turmeric (Curcuma longa) (20)
  • Vitamin D (15)


  1. Ali AT, Crowther NJ. Health risks associated with obesity. J Endocrinol Metab Diabetes South Africa. 2005;10(2):56-61. doi:10.1080/22201009.2005.10872117
  2. Segula D. Complications of obesity in adults: a short review of the literature. Malawi Med J. 2014;26(1):20-24.
  3. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384(9945):755-765. doi:10.1016/S0140-6736(14)60892-8
  4. Eckel RH. Nonsurgical Management of Obesity in Adults. N Engl J Med. 2008;358(18):1941-1950. doi:10.1056/NEJMcp0801652
  5. Gesta S, Tseng Y-H, Kahn CR. Developmental Origin of Fat: Tracking Obesity to Its Source. Cell. 2007;131(2):242-256. doi:10.1016/J.CELL.2007.10.004
  6. Skrypnik K, Suliburska J, Skrypnik D, Pilarski Ł, Reguła J, Bogdański P. The genetic basis of obesity complications. Acta Sci Pol Technol Aliment. 2017;16(1):83-91. doi:10.17306/J.AFS.2017.0442
  7. Adult Overweight and Obesity. Centers for Disease Control and Prevention. Accessed July 10, 2018.
  8. Mumena WA, Francis-Granderson I, Phillip LE, Gray-Donald K. Rapid increase of overweight and obesity among primary school-aged children in the Caribbean; high initial BMI is the most significant predictor. BMC Obes. 2018;5(1):4. doi:10.1186/s40608-018-0182-8
  9. Speakman JR. A Nonadaptive Scenario Explaining the Genetic Predisposition to Obesity: The “Predation Release” Hypothesis. Cell Metab. 2007;6(1):5-12. doi:10.1016/J.CMET.2007.06.004
  10. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532-546.
  11. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity. N Engl J Med. 2005;353(20):2111-2120. doi:10.1056/NEJMoa050156
  12. Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs. 1999;58(4):743-760.
  13. Kaplan LM. Pharmacologic Therapies for Obesity. Gastroenterol Clin North Am. 2010;39(1):69-79. doi:10.1016/j.gtc.2010.01.001
  14. Poston WS, Foreyt JP. Successful management of the obese patient. Am Fam Physician. 2000;61(12):3615-3622.
  15. What are weight-loss dietary supplements and what do they do? Accessed July 10, 2018.
  16. Choi H-C, Kim S-J, Son K-Y, Oh B-J, Cho B-L. Metabolic effects of aloe vera gel complex in obese prediabetes and early non-treated diabetic patients: Randomized controlled trial. Nutrition. 2013;29(9):1110-1114. doi:10.1016/j.nut.2013.02.015
  17. Kucukgoncu S, Zhou E, Lucas KB, Tek C. Alpha-lipoic acid (ALA) as a supplementation for weight loss: results from a meta-analysis of randomized controlled trials. Obes Rev. 2017;18(5):594-601. doi:10.1111/obr.12528
  18. Koh EH, Lee WJ, Lee SA, et al. Effects of Alpha-Lipoic Acid on Body Weight in Obese Subjects. Am J Med. 2011;124(1):85.e1-85.e8. doi:10.1016/j.amjmed.2010.08.005
  19. Namazi N, Larijani B, Azadbakht L. Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials. Clin Nutr. 2018;37(2):419-428. doi:10.1016/j.clnu.2017.06.002
  20. Sun N-N, Wu T-Y, Chau C-F. Natural Dietary and Herbal Products in Anti-Obesity Treatment. Molecules. 2016;21(10):1351. doi:10.3390/molecules21101351
  21. Khossousi A, Binns CW, Dhaliwal SS, Pal S. The acute effects of psyllium on postprandial lipaemia and thermogenesis in overweight and obese men. Br J Nutr. 2008;99(05):1068-1075. doi:10.1017/S0007114507864804
  22. Pal S, Khossousi A, Binns C, Dhaliwal S, Ellis V. The effect of a fibre supplement compared to a healthy diet on body composition, lipids, glucose, insulin and other metabolic syndrome risk factors in overweight and obese individuals. Br J Nutr. 2011;105(01):90-100. doi:10.1017/S0007114510003132
  23. Turnbull WH, Thomas HG. The effect of a Plantago ovata seed containing preparation on appetite variables, nutrient and energy intake. Int J Obes Relat Metab Disord. 1995;19(5):338-342.
  24. Enzi G, Inelmen EM, Crepaldi G. Effect of a hydrophilic mucilage in the treatment of obese patients. Pharmatherapeutica. 1980;2(7):421-428.
  25. Toubro S, Astrup A, Breum L, Quaade F. The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans. Int J Obes Relat Metab Disord. 1993;17 Suppl 3:S73-7; discussion S82.
  26. Breum L, Pedersen JK, Ahlstrøm F, Frimodt-Møller J. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. Int J Obes Relat Metab Disord. 1994;18(2):99-103.
  27. Toubro S, Astrup A. Randomised comparison of diets for maintaining obese subjects’ weight after major weight loss: ad lib, low fat, high carbohydrate diet v fixed energy intake. BMJ. 1997;314(7073):29-34.
  28. Boozer C, Daly P, Homel P, et al. Herbal ephedra/caffeine for weight loss: a 6-month randomized safety and efficacy trial. Int J Obes. 2002;26(5):593-604. doi:10.1038/sj.ijo.0802023
  29. Phung OJ, Baker WL, Matthews LJ, Lanosa M, Thorne A, Coleman CI. Effect of green tea catechins with or without caffeine on anthropometric measures: a systematic review and meta-analysis. Am J Clin Nutr. 2010;91(1):73-81. doi:10.3945/ajcn.2009.28157
  30. Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord. 1992;16(4):269-277.
  31. Hasani-Ranjbar S, Nayebi N, Larijani B, Abdollahi M. A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J Gastroenterol. 2009;15(25):3073-3085.
  32. JK L, C M, KF M, A A. Calcium supplementation for 1 y does not reduce body weight or fat mass in young girls. Am J Clin Nutr. 2006;83:18-23.
  33. Davies KM, Heaney RP, Recker RR, et al. Calcium Intake and Body Weight 1. J Clin Endocrinol Metab. 2000;85(12):4635-4638. doi:10.1210/jcem.85.12.7063
  34. Jacqmain M, Doucet E, Després J-P, Bouchard C, Tremblay A. Calcium intake, body composition, and lipoprotein-lipid concentrations in adults. Am J Clin Nutr. 2003;77(6):1448-1452. doi:10.1093/ajcn/77.6.1448
  35. Buchowski MS, Semenya J, Johnson AO. Dietary calcium intake in lactose maldigesting intolerant and tolerant African-American women. J Am Coll Nutr. 2002;21(1):47-54.
  36. Heaney RP, Davies KM, Barger-Lux MJ. Calcium and weight: clinical studies. J Am Coll Nutr. 2002;21(2):152S-155S.
  37. Mohamed GA, Ibrahim SRM, Elkhayat ES, El Dine RS. Natural anti-obesity agents. Bull Fac Pharmacy, Cairo Univ. 2014;52(2):269-284. doi:10.1016/J.BFOPCU.2014.05.001
  38. Astell KJ, Mathai ML, Su XQ. A Review on Botanical Species and Chemical Compounds with Appetite Suppressing Properties for Body Weight Control. Plant Foods Hum Nutr. 2013;68(3):213-221. doi:10.1007/s11130-013-0361-1
  39. Blankson H, Stakkestad JA, Fagertun H, Thom E, Wadstein J, Gudmundsen O. Conjugated Linoleic Acid Reduces Body Fat Mass in Overweight and Obese Humans. J Nutr. 2000;130(12):2943-2948. doi:10.1093/jn/130.12.2943
  40. Gaullier J-M, Halse J, Høye K, et al. Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans. Am J Clin Nutr. 2004;79(6):1118-1125. doi:10.1093/ajcn/79.6.1118
  41. Risérus U, Smedman A, Basu S, Vessby B. Metabolic effects of conjugated linoleic acid in humans: the Swedish experience. Am J Clin Nutr. 2004;79(6 Suppl):1146S-1148S.
  42. Steck SE, Chalecki AM, Miller P, et al. Conjugated Linoleic Acid Supplementation for Twelve Weeks Increases Lean Body Mass in Obese Humans. J Nutr. 2007;137(5):1188-1193. doi:10.1093/jn/137.5.1188
  43. Whigham LD, Watras AC, Schoeller DA. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Am J Clin Nutr. 2007;85(5):1203-1211. doi:10.1093/ajcn/85.5.1203
  44. Schoeller DA, Watras AC, Whigham LD. A meta-analysis of the effects of conjugated linoleic acid on fat-free mass in humans. Appl Physiol Nutr Metab. 2009;34(5):975-978. doi:10.1139/H09-080
  45. Michishita T, Kobayashi S, Katsuya T, Ogihara T, Kawabuchi K. Evaluation of the Antiobesity Effects of an Amino Acid Mixture and Conjugated Linoleic Acid on Exercising Healthy Overweight Humans: A Randomized, Double-blind, Placebo-controlled Trial. J Int Med Res. 2010;38(3):844-859. doi:10.1177/147323001003800311